Dual inhibition of BRAF for cancer treatment: advances and therapeutic potential

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• BRAF kinase is a key regulator in the MAPK cascade, frequently mutated in cancers such as melanoma and colorectal cancer.
• Selective BRAF inhibitors are limited by drug resistance and compensatory pathway activation.
• Dual-target inhibitors offer a strategy to overcome these limitations by simultaneously inhibiting BRAF and other oncogenic targets.

Purpose of the Study:

• To review the structural and functional roles of BRAF kinase in disease pathogenesis.
• To explore emerging trends in dual-target therapeutic strategies for cancer treatment.
• To evaluate the clinical potential and molecular design challenges of multi-target agents.

Main Methods:

• Literature review of BRAF kinase function, mutation prevalence, and therapeutic targeting.
• Analysis of preclinical data on dual-target inhibitors.
• Examination of modern drug discovery approaches for multi-target agents.

Main Results:

• Dual-target inhibitors demonstrate synergistic disruption of compensatory mechanisms.
• Preclinical models show robust antitumor activity with dual-target agents.
• These inhibitors have the potential to enhance therapeutic effects and reduce off-target toxicity.

Conclusions:

• Dual-target BRAF inhibitors represent a promising therapeutic strategy for managing drug resistance in BRAF-mutated cancers.
• Further research into molecular design and clinical evaluation is crucial for advancing multi-target agents.
• This approach holds significant potential for improving cancer treatment outcomes.